Shares of AB Science S.A. (OTCMKTS:ABSCF – Get Free Report) shot up 14.2% during trading on Monday . The stock traded as high as $1.45 and last traded at $1.45. 1,000 shares traded hands during mid-day trading, an increase of 100% from the average session volume of 500 shares. The stock had previously closed at $1.27.
AB Science Trading Up 14.2%
The business has a 50 day simple moving average of $1.27 and a two-hundred day simple moving average of $1.26.
AB Science Company Profile
AB Science is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the discovery and development of protein kinase inhibitors. Its core focus is on the design of orally administered small-molecule therapies that target key signaling pathways involved in oncology, inflammatory disorders and neurodegenerative diseases. The company’s lead asset, masitinib, is a selective tyrosine kinase inhibitor that has been evaluated in multiple Phase 2 and Phase 3 clinical trials, including studies in mastocytosis, amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and severe asthma.
Since its founding in 2001 by Dr.
Featured Stories
- Five stocks we like better than AB Science
- Do not delete, read immediately
- INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
- Can Any Expenses Be Deducted From Capital Gains Tax?
- The Last Gold Bull Market
Receive News & Ratings for AB Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AB Science and related companies with MarketBeat.com's FREE daily email newsletter.
